No Data
No Data
Yunnan Baiyao Group (000538.SZ) has launched new toothpaste products in recent years, such as High Altitude Liulan and Jing Shuang Peppermint.
On July 11th, Gelonhui reported that Yunnan Baiyao Group (000538.SZ) stated on the investor communication platform that the company has launched new toothpaste products such as Gaodi Liulan and Jinshuang Mint in recent years, which are made with carefully selected soft abrasives, rich in foam, and have a dense paste that can gently clean teeth.
Yunnan Baiyao Group (000538.SZ): The sales revenue from Yunnan Baiyao aerosol contributed more than 1.7 billion yuan, with a year-on-year growth of 15.27%.
Yunnan Baiyao Group (000538.SZ) stated on its investor platform that the sales revenue of Yunnan Baiyao aerosol contributed more than 1.7 billion yuan, a year-on-year increase of 15.27%. Sales of Yunnan Baiyao adhesive plasters, Yunnan Baiyao ointment, Yunnan Baiyao (granules), Yunnan Baiyao capsules and other products have exceeded one hundred million yuan, among which the sales of Yunnan Baiyao ointment exceeded 0.9 billion yuan, the sales of Yunnan Baiyao capsules exceeded 0.6 billion yuan, and the sales of Yunnan Baiyao (granules) and Yunnan Baiyao adhesive plasters exceeded 0.3 billion yuan. Yunnan Baiyao aerosol, function and indications: promoting blood circulation, relieving stasis and swelling, and stopping pain. It is used for contusions and sprains, blood stasis and pain, and muscle soreness.
Yunnan Baiyao Group (000538.SZ): is conducting second-phase development work on Gongxue Ning Capsules, Qixue Kang, and Yunnan Baiyao Capsules.
Yunnan Baiyao Group (000538.SZ) stated on the investor interaction platform that the company is carrying out secondary development work on Gongxue Ning capsules, Qi Xue Kang, and Yunnan Baiyao capsules. In 2023, the clinical observation and research project of 1,791 cases of Gongxue Ning capsules for the treatment of uterine bleeding is expected to be completed, and the clinical trial report is expected to be obtained by the end of 2024. The research on the second development of Qi Xue Kang, used to improve various uncomfortable symptoms of patients with Qi and blood stasis, has been completed. The clinical research project to improve heart and vascular health has completed 70% patient enrollment and the results of some completed trials are statistically analyzed, showing preliminary improvement.
Yunnan Baiyao Group (000538.SZ): Yunnan Baiyao toothpaste will have a domestic market share of 24.6% in 2023.
On July 4, Gelunhui reported that in the field of oral care, Yunnan Baiyao Group is expected to maintain its first market share of 24.6% domestically in 2023, according to Nielsen retail research data YTD2312. In the 2023 November 11 shopping festival-related period, the health products business group achieved multiple firsts: Yunnan Baiyao Tmall toothpaste official flagship store achieved a breakthrough with single-store sales exceeding 100 million yuan for the first time, becoming the first flagship store to break 100 million yuan in sales with a single toothpaste product; it also won the first place on Douyin's toothpaste best-seller list and the Douyin brand toothbrush explosion list.
Yunnan Baiyao Buys Rights on KA-1641 Drug
Yunnan Baiyao Group (000538.SZ) plans to introduce KA-1641, an antibody drug-related patent, to enhance its competitiveness in the field of innovative cancer drugs.
Yunnan Baiyao Group (000538.SZ) announced that the 10th board of directors meeting will be held on June 27, 2024.
No Data